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Identification of a Kavain Analog 
with Efficient Anti-inflammatory 
Effects
Olivier Huck1,2, Xiaxian Han3, Hannah Mulhall3, Iryna Gumenchuk3, Bin Cai  4, James Panek4, 
Radha Iyer3 & Salomon Amar  3
Kavain, a compound derived from Piper methysticum, has demonstrated anti-inflammatory properties. 
To optimize its drug properties, identification and development of new kavain-derived compounds 
was undertaken. A focused library of analogs was synthesized and their effects on Porphyromonas 
gingivalis (P. gingivalis) elicited inflammation were evaluated in vitro and in vivo. The library contained 
cyclohexenones (5,5-dimethyl substituted cyclohexenones) substituted with a benzoate derivative 
at the 3-position of the cyclohexanone. The most promising analog identifed was a methylated 
derivative of kavain, Kava-205Me (5,5-dimethyl-3-oxocyclohex-1-en-1-yl 4-methylbenzoate.) In an in 
vitro assay of anti-inflammatory effects, murine macrophages (BMM) and THP-1 cells were infected 
with P. gingivalis (MOI = 20:1) and a panel of cytokines were measured. Both cell types treated with 
Kava-205Me (10 to 200 μg/ml) showed significantly and dose-dependently reduced TNF-α secretion 
induced by P. gingivalis. In BMM, Kava-205Me also reduced secretion of other cytokines involved in 
the early phase of inflammation, including IL-12, eotaxin, RANTES, IL-10 and interferon-γ (p < 0.05). 
In vivo, in an acute model of P. gingivalis-induced calvarial destruction, administration of Kava-205Me 
significantly improved the rate of healing associated with reduced soft tissue inflammation and 
osteoclast activation. In an infective arthritis murine model induced by injection of collagen-antibody 
(ArthriomAb) + P. gingivalis, administration of Kava-205Me was able to reduce efficiently paw swelling 
and joint destruction. These results highlight the strong anti-inflammatory properties of Kava-205Me 
and strengthen the interest of testing such compounds in the management of P. gingivalis elicited 
inflammation, especially in the management of periodontitis.
Periodontitis is an inflammatory disease leading to the destruction of tooth-supporting tissues, that may be 
induced by dysbiosis1. Over the last decades, several links between periodontitis and systemic diseases have been 
suggested2. Periodontitis has been associated with increased incidences of adverse cardiovascular events, adverse 
pregnancy outcomes, diabetes, and rheumatoid arthritis3–6. Bacterial spreading from diseased periodontal sites 
through the bloodstream has been suggested as one of the major mechanisms involved, since periodontal path-
ogens have been detected in several distant tissues and organs such as blood vessels7 and joints8. The detrimental 
role played by the major periodontal pathogen Porphyromonas gingivalis (P. gingivalis), a keystone pathogen 
implicated in periodontal dysbiosis1,9 has been extensively studied. For example, P. gingivalis is able to invade host 
immune cells and to hijack host immune responses, leading to exacerbated inflammation and tissue destruction, 
both locally and at a distance10,11.
Kavain, a compound extracted from the Piper methysticum plant, has recently been described as a promising 
anti-inflammatory agent and has been evaluated in several in vitro and animal models12–15. In macrophages stim-
ulated by Escherichia coli lipopolysaccharide (LPS), treatment with kavain significantly reduced TNF-α secre-
tion,13 while in another cellular model, kavain was shown to inhibit RANKL-induced osteoclast formation15. In 
an attempt to optimize kavain’s anti-inflammatory effects and to reduce potential side effects, an effort has been 
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made to identify kavain analogs16. One aspect of this effort to synthesize and validate new kavain-analog candi-
dates, has been a focus on the need to reduce the susceptibility of kavain to enzymatic degradation associated with 
the presence of an α-, β-unsaturated lactone moiety. One resulting compound, Kava-241, is a synthesized kavain 
analog that has already demonstrated anti-TNF-α properties and the ability to reduce both P. gingivalis-induced 
periodontitis and arthritis17,18. In macrophages infected with P. gingivalis, the TNF-α decrease observed after 
treatment with this compound was associated with a reduced activation of Toll-like receptor (TLR)-related path-
ways and lipopolysaccharide-induced TNF factor (LITAF)18.
The present study aimed to identify additional new kavain-derived analogs and to evaluate their 
anti-inflammatory properties in vitro and in vivo. The most promising analog identified was Kava-205Me, a meth-
ylated kavain analog.
Materials and Methods
Synthesis of kavain analogs. A useful approach to optimize potential lead compounds is commonly 
referred to as a structure–activity-relationship (SAR) study. Specifically, efforts are directed toward identifying 
the correlations between substructures of compounds and their biological properties. A series of chemical mod-
ifications on the specific sites of the lead compounds are made to improve the potency and pharmaceutical prop-
erties. In our previous SAR study16, we found that one ring-opened analogue bearing an α,β-unsaturated ester 
displayed ≥50% suppression of TNF-α secretion. In addition, medicinal chemistry studies have revealed the 
effect of a methyl group in promoting and enhancing compound potency19,20. In light of these findings, we gener-
ated a focused library of cyclohexenones (5,5-dimethyl substituted cyclohexenones) substituted with a benzoate 
derivative at the 3-position of the cyclohexanone, which included the analog Kava-205Me (Fig. 1A). Kava-205Me 
was tested in vitro at the concentration ranging from 10, 50, 200 μg/ml.
Porphyromonas gingivalis culture. The Porphyromonas gingivalis 381 strain was cultured and maintained 
in brain-heart infusion media supplemented with hemin (5 μg/mL, Sigma-Aldrich, St. Louis, MO), and menadi-
one (1 μg/mL, Sigma-Aldrich, St. Louis, MO) in an anaerobic environment (AnaeroPack-Anaero, Mitsubishi Gas 
Chemical Co.; New York, NY) as previously described10.
Mouse bone marrow macrophage (BMM) isolation and infection. BMM were isolated from 
mouse bone marrow as previously described10. Briefly, after euthanasia, femurs and tibias were harvested and 
the bone marrow was flushed from the medullar cavity with collection media (DMEM, 10% FBS, and 1% 
penicillin-streptomycin). Cells were cultured in 30% L-929 conditioned RPMI media at a density of 105 cells/mL. 
L-929 (ATCC no. CCL-1) is a murine fibroblast cell line that is used as a source of macrophage colony-stimulating 
factor (M-CSF)21. After one week, cells had differentiated into BMM. The day of infection, cells were seeded in 
a 24-wells plate and after PBS wash, P. gingivalis 381 was added for 4 h to the BMM cultures at a MOI = 20:122.
Figure 1. (A) The synthesis of Kava-205Me is based on the O-acylation of the highly enolizable 
cyclic 1,3-diketones. Accordingly, treatment of 1,2-dichloroethane solution of commercially available 
1,3-cyclohexanedione with 4-methylbenzoyl chloride in the presence of pyridine efficiently provided the 
O-acylated enol derivative Kava-205Me. (B) Kava-205 chlorinated and methylated forms reduce TNF-α in 
BMM infected with P. gingivalis. Kavain derived compounds identified through SAR were tested (40 μg/ml). 
Compounds were plotted according to z-score of TNF-α inhibition. Chemical formula and structure of others 
tested analogs are presented in Supplementary Fig. 1.
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THP-1 cell culture. THP-1 (ATCC® TIB-202™) cells were grown in RPMI medium containing 1% peni-
cillin/streptomycin, 10% fetal bovine serum and β-mercaptoethanol (0.05 mM) in 5% CO2 at 37°. Infection was 
performed as described for BMM.
TNF-α ELISA. The supernatants from infected cells and mouse serum were evaluated by ELISA for the detec-
tion of TNF-α concentration with an Invitrogen kit (KMC3011, ThermoFisher, Dublin, OH, USA). ELISA immu-
noreactivity was quantified using a microplate reader (Bio-Rad, Hercules, CA, USA).
Bioplex pro Mouse cytokine 23-plex assay. A cytokine 23-plex kit (BioRad, CA, USA, Cat 
#M60009RDPD) was used according to manufacturer’s instructions to measure the concentrations of eotaxin, 
G-CSF, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, 
IL-17A, KC MCP-1 (MCAF), MIP-1α, MIP-1β, RANTES, and TNF-α in supernatants from BMM. The fluores-
cent signal intensity was measured using Bioplex 200 system. Cytokine concentrations were determined using 
standard curves generated using Bioplex manager software (V4.1).
RNA extraction and quantitative real-time PCR (qRT-PCR). Total RNA from BMM was isolated and 
purified with a Rneasy Mini kit according to the manufacturer’s instructions (Qiagen, Hilden, DE, USA). cDNA 
from total RNA was synthesized (50–100 ng RNA/20 μl) using a QuantiTect Reverse transcription kit according 
to the manufacturer’s instructions (Qiagen). qRT-PCR was performed using the Taqman Fast Advanced Master 
Mix (Applied Biosystems, Foster City, CA, USA) and was run for the following gene using the probe provided by 
Thermofisher: acid phosphatase 5 (ACP5) (Mn00475698_m1). qRT-PCR assays were performed in duplicates on 
an Applied Biosystems QuantStudio 5 Real-Time PCR system. The data were analyzed using QuantStudio 5 soft-
ware V1.4. The gene expression levels were normalized to β-actin for BMM samples respectively and expressed 
relative to unstimulated controls following the 2-ΔΔCT method.
Mouse calvarial bone resorption model. The 8- to 12-week-old wild-type C57BL/6 J mice used in this 
study were purchased from Taconic Laboratories (Germantown, NY). All mice were housed 3/cage at the New 
York Medical College Animal Facility, on a 12 h light dark cycle and ad libitum access to food and water. All ani-
mals were cared by veterinary staff for house boundary, biological analysis and maintenance. All procedures were 
approved by the NYMC IACUC committee and follow ARRIVE guidelines. The mice were randomly allocated 
into the following three groups (5 mice/group): (i) PBS (ii) P. gingivalis (iii) P. gingivalis + Kava-205Me concur-
rently. Mice were anesthetized by intraperitoneal injection of ketamine-xylazine. The heads of mice were shaved, 
and then live bacteria resuspended in 100 μl of PBS were injected subcutaneously with a 30.5-gauge needle at a 
point on the midline of the skull between the ears and eyes, as we have described previously10. The dose of P. gin-
givalis (5 × 108) was injected. In the treatment group, 1 mg of Kava-205Me was concurrently injected. Mice were 
euthanized 4 days post injection. The size of the lesion (area in square millimeters) resulting from the injection in 
each animal was analyzed using ImageJ software.
Induction of arthritis and scoring. Six-weeks-old, pathogen-free DBA1/BO male mice were obtained 
from Taconic Laboratories. Arthritis was induced by two consecutive intraperitoneal injections of ArthritoMab 
(AB) antibody cocktail (Chondrex, WA, USA). 3.5 mg were injected at baseline and a second injection of 1 mg 
was done at day 4. A sample of 5 mice/group was considered based on our previous data18 and all animals were 
randomly allocated in each group. For P. gingivalis injected groups, 3 intraperitoneal injections of 5 × 108 bacte-
ria/100 μl were administered. Mice were euthanized after 35 days by CO2 inhalation. All four paws were evaluated 
by a reviewer blinded to the treatment group to score arthritis using a visual qualitative assessment scoring as 
follows: (0) no paw swelling, (1) mild swelling, (2) moderate swelling, (3) severe swelling.
Injection of P. gingivalis and Kava-205Me compound. In Kava-205Me treated groups, 8 intraperito-
neal injections (40 mg/kg) were administered. The first injection was performed 3 days after the first AB injection 
(day 0) and at days 5, 7, 10, 13, 14, 18. As a control, same volume of the DMSO used to dissolve Kava-205 powder 
was used.
Tissue preparation. Phalangeal joints and intact surrounding tissues were fixed with 4% freshly prepared 
paraformaldehyde (Sigma-Aldrich, St. Louis, MO) in PBS (pH 7.2) for 24 h at 4 °C. Following fixation, specimens 
were consecutively washed with 5%, 10%, and 15% glycerol (American Bioanalytical, Natick, MA) in PBS, each 
for 15 min at 4 °C and decalcified in an EDTA solution (Sigma-Aldrich, St. Louis, MO) for 14 days at 4 °C. Samples 
were then immersed in 30% sucrose (Sigma-Aldrich, St. Louis, MO) in PBS until embedding. Tissue blocks were 
embedded with a HISTOPREP® compound (Fisher Scientific, Hanover Park, IL) for cryostat sectioning. Serial 
mesiodistal sections (5 μm) parallel to the long axis of the phalangeal joint were made and stained with hematox-
ylin (Fisher Scientific, Pit, IL) – eosin (ACROS Organics, Morris Plains, NJ).
TRAP staining. Osteoclasts were detected by TRAP staining. 5 µm thick histological slides were exposed to 
the TRAP solution containing N,N-dimethylformamide (EM Science), 3.7 mM of fast red violet LB di-azonium 
salt (Sigma), 6.4 mM of tartaric acid (Sigma), and 0.4% MgCl2 in 0.2 M sodium acetate buffer (pH 5.0) for 10 min-
utes at 37 °C. The slides were then washed for 30 minutes before being counter-stained with hematoxylin for 
5 seconds. Osteoclasts were identified as being positively stained for TRAP and possessing a ruffled border with 
an underlying lacuna.
Histological scoring. Samples were scored for inflammation, bone destruction, bone formation/repair 
and for cartilage destruction. To score inflammation, a 0–4 scale was used with 0 corresponding to no signs of 
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inflammation, 1 to mild infiltration of inflammatory cells, 2 to mild inflammation with small hyperplasia in the 
synovial lining layer, 3 to synovial edema, hyperplasia and more pronounced inflammation, and 4 to severe syno-
vial hyperplasia and cellular infiltration. Bone destruction was scored using a 0 to 4 scale with 0 corresponding to 
no signs of bone destruction, 1 to osteoclast activation, 2 to presence of some osteoclast lacunae, 3 to presence of 
many osteoclast lacunae and signs of bone resorption, and 4 to severe bone resorption and erosion.
Bone histomorphometry. For each animal, two slides, each containing three tissue sections with the larg-
est number of bone marrow cells (six specimens total), were analyzed. For each tissue section, the microscopic 
fields with the most resorption were studied. The osteoclast index, which represents the number of osteoclasts per 
millimeter of trabecular bone surface, was measured.
The percentage of bone surface covered by osteoclasts was also quantified. This was calculated as the sum 
of the lengths of the osteoclasts containing lacunae (active eroded area) divided by the total trabecular bone 
perimeter.
Statistical analysis. All experiments have been performed at least in triplicate. Data were analyzed for statis-
tical significance with XLStat (Addinsoft, New York, NY, USA). P values were calculated with the Mann-Whitney 
U-test or ANOVA one-way t-test for multiple comparisons. Results were considered significant at *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001. Data are presented as mean ± standard error of the mean (SEM).
Results
Screening of selected kavain-derived analogs leads to identification of Kava-205Me. To iden-
tify compounds with strong anti-inflammatory properties, kavain analogs were tested in a screening assay based 
on TNF-α inhibition in BMM infected with P. gingivalis (Fig. 1B). The chemical structure of all tested compounds 
is described in Fig. 1 Supplemental Information. This screen identified Kava-205Cl (5,5-dimethyl-3-oxocyclohex-
1-en-1-yl 4-chlorobenzoate) and its methylated analog Kava-205Me (5,5-dimethyl-3-oxocyclohex-1-en-1-yl 
4-methylbenzoate) (Fig. 1B) as effective inhibitors of TNF-α secretion (z = −0.99 and z = −1.07 respectively). 
In THP-1 and BMM infected with P. gingivalis, a dose-response evaluation was performed and showed that 
treatment with Kava-205Me reduced significantly TNF-α secretion even at the lowest tested dose (10 μg/ml) 
(Fig. 2A,B) emphasizing the anti-inflammatory effect of tested compound in both murine and human cells. 
Moreover, no significant cytotoxicity was observed when using Kava-205Me at 10 and 50 μg/ml concentrations in 
vitro (Supplementary Fig. 2). Therefore, the 50 μg/ml concentration was selected for further experiments.
Kava-205Me significantly reduced P. gingivalis-induced cytokine secretion from mac-
rophages. P. gingivalis is able to induce sustained recruitment of immune cells such as neutrophils and 
T-lymphocytes, whose presence is associated with excessive inflammation and tissue destruction at infectious 
sites. To evaluate the effect of Kava-205Me on the secretion of chemokines and cytokines from BMM exposed 
to P. gingivalis, a multiplex analysis was performed that compared P. gingivalis infected cells with and without 
treatment with Kava-205Me. As expected, P. gingivalis infection significantly increased secretion of IL-12, IFN- γ, 
MIP-1β, RANTES, IL-10, G-CSF and eotaxin. Treatment with Kava-205Me (50 μg/ml) significantly reduced the 
concentrations of such chemokines and cytokines (Fig. 3). Moreover, the gene expression of ACP5, an osteo-
clast specific gene, was evaluated in BMM infected with P. gingivalis with or without Kava-205Me treatment. As 
observed for inflammatory cytokines, P. gingivalis increased significantly ACP5 gene expression and Kava-205Me 
treatment reduced its expression illustrating a potential protective effect on bone (Fig. 2C).
Kavain-205Me reduced P. gingivalis-induced calvarial destruction. In an acute model of P. gingi-
valis infection, Kava-205Me was administered to evaluate its anti-inflammatory and pro-healing properties in 
vivo. In this calvarial model, injection of P. gingivalis induced formation of a cutaneous abscess characterized by 
dermal inflammation and bone destruction (Fig. 4). Administration of Kava-205Me significantly increased the 
rate of healing (Fig. 4B). At the histological level, treatment with Kava-205Me reduced significantly soft tissue 
inflammation (Fig. 4C,D). Moreover, a trend of reduction in osteoclastic activity was also observed after treat-
ment (Fig. 4D).
Systemic administration of Kava-205Me significantly reduced infective arthritis- associated 
joint destruction. To evaluate the systemic effect of Kava-205Me, an infective arthritis was induced in mice 
by the combined insults of P. gingivalis and AB peritoneal injection. After 10 days, significant paw swelling was 
observed, confirming the establishment of joint inflammation and a destructive process (Fig. 5). Interestingly, sys-
temic administration of Kava-205Me significantly decreased P. gingivalis-induced paw swelling at the 32 day time 
point (Fig. 5A,B). This anti-inflammatory effect was confirmed histologically (Fig. 5C). A significant reduction 
of the inflammatory infiltrate in paw tissue sections was observed in animals exposed to P. gingivalis and treated 
by Kava-205Me. In contrast, untreated P. gingivalis exposed animals. exhibited a significant inflammatory infil-
trate dominated by neutrophils and lymphocytes at the same time point (Fig. 5C). Congruent with these results, 
Kava-205Me treatment of P. gingivalis-exposed animals was also found to reduce the osteoclastic activity of the 
infiltrate, as evidenced by a reduction in the number of TRAP positive multinucleated cells in contact with bone. 
In contrast, P. gingivalis-exposed animals left untreated exhibited a significant increase of the number of TRAP 
positive multinucleated cells in contact with bone (Fig. 5C,D).
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Discussion
This study identifies a promising new kavain derivative, Kava-205Me, with clear anti-inflammatory and 
pro-healing properties in vitro and in vivo. Kava-205Me demonstrated the ability of reducing inflammatory 
cytokines and chemokines secretion in human and murine macrophages induced by P. gingivalis infection. In 
vivo, it significantly reduced P. gingivalis -associated inflammation and tissue destruction in both acute and 
chronic infection models.
Kavain is a natural product, long used as an anti-anxiety and anti-inflammatory drug in traditional medicines 
of the Pacific islands. It has been shown to reduce secretion of pro-inflammatory cytokines, especially TNF-α, 
in several cell types12–14,23. However, due to the side effects (hepatic, neurologic, and dermatological toxicity) 
associated with its use and to optimize its pharmacological properties, there is a recognized need to identify new 
kavain analogs24. Kava-205Me is a newly identified active compound bearing a para-methyl substituted phenyl 
ring which varies electronically and sterically from the para-chloro analog, where the chlorine atom is electron 
withdrawing, decreasing the chemical and metabolic stability of the vinylogous anhydride linkage. When com-
pared to natural kavain, which is susceptible to degradation because of its lactone functional group, Kava-205Me 
may be metabolically stabilized by the replacement of the lactone function with a cyclic α,β-unsaturated enone 
system, (or vinylogous anhydride) thereby showing enhanced anti-inflammatory effects compared to kavain. 
These unique, but subtle structural features of Kava-205Me may be responsible for its enhanced performance as 
shown in this study. We speculate that methylation of Kava-205Me most likely increases efficacy by enhancing 
metabolic stability.
Figure 2. Kava-205Me (10, 50, 200 μg/ml) reduced significantly TNF-α secretion induced by P. gingivalis in 
supernatants of human THP1 cells (A) and in BMM (B) in a dose-dependent manner. Kava-205Me (50 μg/ml) 
reduced significantly ACP5 gene expression in BMM infected with P. gingivalis (C). **p < 0.01; ***p < 0.001.
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Herein, the anti-TNF-α property of Kava-205Me was demonstrated in vitro in macrophages of both human 
and murine origin. Additionally, it was shown that Kava-205Me was also able to modulate the concentrations 
of secreted cytokines and chemokines including IL-12, IFN-γ and RANTES in cultures of P. gingivalis infected 
macrophages. Also, an impact was observed at short term on IL-10, a cytokine well-known to be increased in 
Figure 3. Effect of Kava-205Me treatment on cytokine secretion from P. gingivalis-stimulated BMM. The 
BioPlex Pro Mouse Cytokine 23-plex Assay was utilized to determine the cytokine levels in BMM culture 
supernatants stimulated with P. gingivalis for 4 hrs. The data presented are means of 3 replicates. Eight of 23 
cytokines showed significant reductions after Kava-205Me treatment (50 μg/ml). Unpaired t-test was performed 
for P. gingivalis vs P. gingivalis + Kava-205Me (*p < 0.05; **p < 0.01; ***p < 0.001).
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the first phase of P. gingivalis infection to escape immune response suggesting an impact of Kava-205Me on the 
rescue of immune response10,25. These cytokines are associated to periodontitis development and have already 
been shown to be activated by P. gingivalis infection, contributing to inflammation and neutrophil recruitment at 
lesion sites26–29. These cytokines and others are key mediators involved in the host-immune response and tissue 
destruction through activation of proteases such as matrix metalloproteinases (MMPs)27. Nevertheless, we also 
demonstrated, for the first time, the protective role of Kava-205Me on bone destruction. Treatment with Kava-
205Me reduced significantly ACP5 expression in infected BMM, a marker of osteoclast differentiation, activation 
and proliferation. Such effect was already demonstrated for others drugs such as fluvastatin30 emphasizing the 
potential for Kava-205Me in the management of bone destructive diseases.
The anti-inflammatory properties of kavain and its derivatives in multiple cell types such as macrophages, 
osteoblasts and even adipocytes are now well described12,14,15,18. Interestingly, such effects are mediated by several 
pathways involved in NFκB activation including ERK/LITAF13 and peroxisome proliferation–activated receptor 
γ coactivator α (PGC-1α)12 leading to the control of other detrimental biological events such as oxidative stress. 
Figure 4. Effect of Kava-205Me on calvarial healing. Injection of Kava-205Me (1 mg) significantly decreased 
P. gingivalis-induced calvarial destruction. After 4 days, calvarial wounds in treated mice had largely closed 
while wounds in untreated mice still exhibited large lesions (A,B). At the histological level, a decreased number 
of inflammatory cells within soft tissue was observed in the Kava-205Me group, and fewer for TRAP positive 
cells were observed (C). Quantitative evaluation of histological changes following Kava-205Me treatment 
(inflammation score; osteoclast index, osteoclast-covered surface) (D). *p < 0.05.
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This broad spectrum of action will be of interest in the management of several acute and chronic inflammatory 
diseases of infectious origin. However, it is clear that not every analog behaves like its parent molecule and there-
fore, a large-scale analysis should be conducted to determine all molecular pathways affected by Kava-205Me.
Figure 5. Effect of Kava-205Me in infective arthritis model. Clinical examination of forepaws (A) and clinical 
score of arthritis (B) were evaluated daily in all groups. Pictures were taken at 10 and 32 days. Note the swollen 
paws in P. gingivalis + AB group and the significant reduction in Kava-205Me treated group; *p < 0.05. 
Histological views of the joint (C) (H-E staining for inflammation and TRAP staining. Histological sections 
performed at the joint site are representative of each group. AB + P. gingivalis injected group was associated 
with intense infiltrate of inflammatory cells, predominantly neutrophils macrophages and lymphocytes. 
Furthermore, signs of edema and synovial hyperplasia were clearly observed. Treatment with Kava-205Me 
reduced significantly such signs of inflammation and tissue destruction. Quantitative evaluation of histological 
changes following Kava-205Me treatment (inflammation score; osteoclast score) (D). *p < 0.05.
9Scientific RepoRtS |         (2019) 9:12940  | https://doi.org/10.1038/s41598-019-49383-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
To confirm the observed effect in vivo, administration of Kava-205Me was administered to mice in acute 
and chronic inflammation models. In a model of P. gingivalis induced calvarial destruction, injection of Kava-
205Me at the lesion site promoted wound healing. P. gingivalis is a destructive bacterium and its inoculation at 
calvarial site induces formation of an abscess, inflammation of soft tissues, and destruction of underlying bone10. 
Treatment with Kava-205Me significantly reduced recruitment of inflammatory cells and subsequent bone 
destruction. Such effects may be correlated to the observed reduction of secretion of pro-inflammatory cytokines; 
however, additional studies are required to determine which phase(s) of the inflammatory response31 is/are most 
affected by Kava-205Me. Kava-205Me also contributed to reduce joint inflammation and tissue destruction in 
an infective arthritis model triggered by P. gingivalis. Treatment reduced inflammatory cell infiltration within 
soft tissues and also decreased osteoclastic activity. These results are consistent with those obtained in a model of 
ovariectomy-induced bone loss where kavain was suggested as a candidate drug for the pharmacological manage-
ment of osteolytic diseases15. Indeed, it has been demonstrated that kavain is able to inhibit receptor activator of 
nuclear factor‐κB ligand (RANKL)-induced osteoclast differentiation and associated bone resorption15.
The anti-inflammatory properties of Kava-205Me led to decreases in P. gingivalis-induced inflammation and 
bone destruction. This promising compound should be studied further for its potential therapeutic applications 
in other acute and chronic inflammatory diseases and development of adapted scaffold should be conducted.
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